The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy.
The complement system effectively identifies and clears invasive pathogens as well as injured host cells. Uncontrolled complement activation can also contribute to tissue injury, however, and inhibition of this system may ameliorate many types of inflammatory injury. Several studies have demonstrated that the filtration of complement proteins into the renal tubules, as occurs during proteinuric renal disease, causes tubular inflammation and injury. In the present study, we tested the hypothesis that activation of the complement system in the urinary space requires an intact alternative pathway. Using a model of adriamycin-induced renal injury, which induces injury resembling focal segmental glomerulosclerosis, we examined whether mice deficient in factor B would be protected from the development of progressive tubulointerstitial injury. Complement activation was attenuated in the glomeruli and tubulointerstitium of mice with congenital deficiency of factor B (fB-/-) compared with wild-type controls, demonstrating that complement activation does occur through the alternative pathway. Deficiency in factor B did not significantly protect the mice from tubulointerstitial injury. However, treatment of wild-type mice with an inhibitory monoclonal antibody to factor B did delay the development of renal failure. These results demonstrate that complement activation in this nonimmune complex-mediated model of progressive renal disease requires an intact alternative pathway.
Lenderink
Amanda M
AM
Department of Medicine, University of Colorado, Denver, USA.
Liegel
Katharine
K
Ljubanović
Danica
D
Coleman
Kathrin E
KE
Gilkeson
Gary S
GS
Holers
V Michael
VM
Thurman
Joshua M
JM
D000419:Albuminuria / Q000139:chemically induced / Q000378:metabolism; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015153:Blotting, Western; D011415:Complement Factor B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D003170:Complement Pathway, Alternative / Q000502:physiology*; D004317:Doxorubicin / Q000633:toxicity*; D005455:Fluorescent Antibody Technique; D007674:Kidney Diseases / Q000139:chemically induced* / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000473:pathology / Q000503:physiopathology*; D007684:Kidney Tubules / Q000473:pathology / Q000503:physiopathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011507:Proteinuria / Q000139:chemically induced / Q000503:physiopathology
D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D004317:Doxorubicin; D011415:Complement Factor B